ERBB2 and neoplasm: In our preclinical in vivo PET studies, [64Cu]Cu-DOTAGA-ch14.18/CHO revealed high tumor accumulation with a %ID/g of 31.6 ± 5.8; this is at least on par with other radiolabeled antibodies such as HER2/neu-specific trastuzumab 44 and EGFR-specific cetuximab 45.